AAV vectors are estimated at 46.0% by vector type in 2026, with chromatography projected at 42.0% and gene therapy at 57.0%. Adoption depends on preserving functional particles during impurity clearance, while serotype differences and scale transfer can alter recovery.
Vector Purification Market Analysis By Purification TechniqueVector Purification Market Analysis By Scale Of OperationVector Purification Market Analysis By Therapeutic AreaVector Purification Market Analysis By Type Of TherapyVector Purification Market Breakdown By Vector Type, Purification Technique, And RegionVector Purification Market Opportunity Matrix Growth Vs Value